Trading Signals: TNXP Stock Price Prediction and Forecast (Fri. Feb. 3, 2012 - Fri. May. 13, 2022)(Tonix Pharmaceuticals)
| TNXP latest price $301.0000 (6.36%) ($282.0000 - $303.0000) on Fri. May. 4, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.63% (three month average) | RSI | 45 | Latest Price | $301.0000(6.36%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TNXP declines -1.2% a day on average for past five trading days. | Weekly Trend | TNXP declines -3% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TNXP advance at 0% a week (0% probability) IWO(11%) ARKG(10%) IBB(10%) IPO(10%) IWC(10%) | Factors Impacting TNXP price | TNXP will decline at least -1.315% in a week (0% probabilities). TLT(-7%) GLD(-7%) SIL(-6%) GDX(-6%) BWX(-6%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.315% (StdDev 2.63%) | Hourly BBV | 0 () | Intraday Trend | 5.6% | | | |
|
Resistance Level | $309.63 | 5 Day Moving Average | $301.6(-0.2%) | 10 Day Moving Average | $306.87(-1.91%) | 20 Day Moving Average | $309.63(-2.79%) | To recent high | -17.3% | To recent low | 6.4% | Market Cap | $79.765b | | | | Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.July 16, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has entered into a research collaboration and option agreement with Columbia University focused on studying the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic. The research collaboration will focus on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19 at the cellular level including human monoclonal antibodies and anti-idiotypes. The research is designed to fill in important gaps in understanding the detailed immune responses to COVID-19, and to provide a foundation upon which to target vaccines and therapeutics to appropriate individuals by precision medicine. |